PEN241220P280000
- 36.20
- -76.00-67.74%
Penumbra Newsroom
Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)
ABT Stock Benefits From First Patient Procedures With TAVI System
Penumbra Is Maintained at Buy by BTIG
International Expansion Supports BSX Stock Amid Macroeconomic Woes
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization With New FDA-Approved Technologies
Express News | Penumbra Inc : Leerink Partners Raises Target Price to $262 From $240
Insider Sale: CEO and President of $PEN (PEN) Sells 3,281 Shares
Penumbra(PEN.US) Officer Sells US$3.56 Million in Common Stock
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating
3 Reasons Growth Investors Will Love Penumbra (PEN)
Form 144 | Penumbra(PEN.US) Insider Proposes to Sell 7.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 20, $Penumbra(PEN.US)$ Insider Adam Elsesser intends to sell 30,000 shares of its common stock on Nov 20, with a total market value of approximately $7.11 million. Adam
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Breaking Down Penumbra: 11 Analysts Share Their Views
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Analyst Ratings
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250
Express News | Penumbra Inc : Piper Sandler Raises Target Price to $250 From $235